{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:03:49Z","timestamp":1791687829297,"version":"4.3.4"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902745 82103228"],"award-info":[{"award-number":["81902745 82103228"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2018JJ3716 2019WK2071"],"award-info":[{"award-number":["2018JJ3716 2019WK2071"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M693557"],"award-info":[{"award-number":["2021M693557"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-\u03baB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co-Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10\u00a0years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK-RANKL-OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost-effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.<\/jats:p>","DOI":"10.3389\/fphar.2022.929223","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T05:27:32Z","timestamp":1663565252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A bibliometric research based on hotspots and frontier trends of denosumab"],"prefix":"10.3389","volume":"13","author":[{"given":"Bolin","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2106\/JBJS.K.00774","article-title":"Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the FREEDOM trial","volume":"94","author":"Adami","year":"2012","journal-title":"J. Bone Jt. Surg. Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"","journal-title":"J. Bone Min. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"","journal-title":"Eur. J. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e10217","DOI":"10.1002\/jbm4.10217","article-title":"Effect of denosumab on femoral periprosthetic BMD and early femoral stem subsidence in postmenopausal women undergoing cementless total hip arthroplasty","volume":"3","author":"Aro","year":"2019","journal-title":"JBMR Plus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: Three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1097\/TP.0000000000001547","article-title":"Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab","volume":"101","author":"Bonani","year":"2017","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"23","author":"Bonnet","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2215\/CJN.11371015","article-title":"Bone disease after kidney transplantation","volume":"7","author":"Bouquegneau","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: Analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J. Bone Min. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2021.3.FOCUS201049","article-title":"Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: Their impact on the biology of fusion and systematic review of the literature","volume":"50","author":"Bryant","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: From primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/14712598.2012.674507","article-title":"Emerging trends in regenerative medicine: A scientometric analysis in CiteSpace","volume":"12","author":"Chen","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"317ra197","DOI":"10.1126\/scitranslmed.aad0295","article-title":"RANKL blockade prevents and treats aggressive osteosarcomas","volume":"7","author":"Chen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/15384101.2017.1310353","article-title":"Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab","volume":"16","author":"Cuy\u00e0s","year":"2017","journal-title":"Cell Cycle"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nep.13028","article-title":"Management of mineral and bone disorders in renal transplant recipients","volume":"22","author":"Damasiewicz","year":"2017","journal-title":"Nephrology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am. J. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/14712598.2020.1790522","article-title":"Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: An intriguing perspective","volume":"20","author":"Deligiorgi","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14712598.2020.1814731","article-title":"Denosumab for cancer-related bone loss","volume":"20","author":"Dell'Aquila","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 Years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J. Bone Min. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00198-020-05413-0","article-title":"Osteoporosis in the age of COVID-19","volume":"31","author":"Girgis","year":"2020","journal-title":"Osteoporos. Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1172\/JCI112838","article-title":"Human giant cell tumors of bone identification and characterization of cell types","volume":"79","author":"Goldring","year":"1987","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jtho.2015.10.001","article-title":"Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review","volume":"11","author":"Hendriks","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"20","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.bonr.2020.100293","article-title":"Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment","volume":"13","author":"Hirooka","year":"2020","journal-title":"Bone Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"753185","DOI":"10.3389\/fendo.2021.753185","article-title":"Four-year teriparatide followed by denosumab vs. Continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment","volume":"12","author":"Hirooka","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1007\/s12325-020-01395-x","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, randomized controlled phase 3 study-asian subgroup Analysis","volume":"37","author":"Huang","year":"2020","journal-title":"Adv. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.otsr.2018.07.015","article-title":"Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion","volume":"104","author":"Ide","year":"2018","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"dgz095","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Min. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): Extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: Results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J. Bone Min. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"580605","DOI":"10.3389\/fonc.2020.580605","article-title":"Denosumab in giant cell tumor of bone: Current status and pitfalls","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/JPR.S258739","article-title":"Research trends of acupuncture therapy on knee osteoarthritis from 2010 to 2019: A bibliometric analysis","volume":"13","author":"Li","year":"2020","journal-title":"J. Pain Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","article-title":"Comparison of denosumab and bisphosphonates in patients with osteoporosis: A meta-analysis of randomized controlled trials","volume":"104","author":"Lyu","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 Months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12957-016-1034-y","article-title":"Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series","volume":"4","author":"M\u00fcller","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women","volume":"5","author":"Nakamura","year":"","journal-title":"Bone Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"17021","DOI":"10.1038\/boneres.2017.21","article-title":"Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment","volume":"5","author":"Nakamura","year":"","journal-title":"Bone Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11657-017-0371-y","article-title":"Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis","volume":"12","author":"Nakamura","year":"","journal-title":"Arch. Osteoporos."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for bronj development?","volume":"43","author":"Otto","year":"2015","journal-title":"J. Craniomaxillofac. Surg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s11695-018-3202-3","article-title":"Correction to: Which bariatric procedure is the most popular in the world? A bibliometric comparison","volume":"28","author":"Ozsoy","year":"2018","journal-title":"Obes. Surg."},{"key":"B53","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0300891618784808","article-title":"Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results","volume":"104","author":"Palmerini","year":"2018","journal-title":"Tumori"},{"key":"B54","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J. Bone Min. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-014-2955-1","article-title":"RANK expression as a prognostic and predictive marker in breast cancer","volume":"145","author":"Pfitzner","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"B56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00264-021-05163-6","article-title":"Research trends of platelet-rich plasma application in orthopaedics from 2002 to 2020: A bibliometric analysis","volume":"45","author":"Ren","year":"2021","journal-title":"Int. Orthop."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: Final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B61","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J. Bone Min. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12253-017-0362-8","article-title":"In vitro study of the effects of denosumab on giant cell tumor of bone: Comparison with zoledronic acid","volume":"25","author":"Shibuya","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: A randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J. Bone Min. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3111\/13696998.2012.675380","article-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"15","author":"Stopeck","year":"2012","journal-title":"J. Med. Econ."},{"key":"B69","doi-asserted-by":"publisher","first-page":"E272","DOI":"10.3390\/nu10030272","article-title":"Vitamin D and calcium addition during denosumab therapy over a period of four years significantly improves lumbar bone mineral density in Japanese osteoporosis patients","volume":"27","author":"Suzuki","year":"2018","journal-title":"Nutrients"},{"key":"B70","first-page":"724","article-title":"CiteSpace II: Visualization and knowledge discovery in bibliographic databases","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu. Symp. Proc."},{"key":"B71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14989\/ActaUrolJap_66_1_23","article-title":"A case of atypical femoral fracture after dosing denosumab","volume":"66","author":"Takahashi","year":"2020","journal-title":"Hinyokika Kiyo."},{"key":"B72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1620\/tjem.242.115","article-title":"Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta","volume":"242","author":"Uehara","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"Von Moos","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.4103\/1673-5374.257535","article-title":"Mapping theme trends and knowledge structures for human neural stem cells: A quantitative and co-word biclustering analysis for the 2013-2018 period","volume":"14","author":"Wei","year":"2019","journal-title":"Neural Regen. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"556022","DOI":"10.3389\/fmed.2021.556022","article-title":"Investigating research hotspots and publication trends of spinal stenosis: A bibliometric analysis during 2000-2018","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00774-020-01175-1","article-title":"Discovery of the RANKL\/RANK\/OPG system","volume":"39","author":"Yasuda","year":"2021","journal-title":"J. Bone Min. Metab."},{"key":"B81","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J. Bone Min. Metab."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jbmr.4049","article-title":"Osteoporosis management in the era of COVID-19","volume":"35","author":"Yu","year":"2020","journal-title":"J. Bone Min. Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"B84","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fcell.2020.00325","article-title":"Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jot.2019.08.004","article-title":"The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review","volume":"22","author":"Zhu","year":"2020","journal-title":"J. Orthop. Transl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.929223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T05:27:41Z","timestamp":1663565261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.929223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":85,"alternative-id":["10.3389\/fphar.2022.929223"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.929223","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"article-number":"929223"}}